Ironwood Pharmaceuticals (NASDAQ: IRWD) proposes resale of RSU-derived shares

Rhea-AI Filing Summary

Ironwood Pharmaceuticals, Inc. submitted a Form 144 proposing resale of Class A common stock derived from restricted stock unit awards. The filing lists grant-dated lots of shares awarded on 03/02/2022, 03/08/2023, 02/12/2024, and 02/10/2025.

The excerpt includes per-lot quantities, including 16,969 and 16,375 shares as examples; these lots are described as restricted stock unit awards under the company's equity incentive plan. Timing and aggregate resale proceeds are not provided in the excerpt.

Insights

Securities Compliance Counsel

Form 144 lists RSU-derived share lots proposed for resale; specific timing and proceeds are not shown.

The filing identifies four restricted stock unit awards with grant dates and per-lot share counts, which the reporting person intends to sell under Rule 144 procedures. The listed entries include grant dates and share counts tied to the issuer's equity incentive plan.

Execution, transfer agent processing, and suitability for sale depend on meeting Rule 144 holding-period and volume limitations; subsequent filings will disclose actual transactions and aggregate proceeds when sales occur.

Equity Compensation Specialist

Reported lots reflect vested/issuable RSU awards rather than open-market purchases.

The rows label each lot as a "Restricted Stock Unit award" with grant dates of 03/02/2022, 03/08/2023, 02/12/2024, and 02/10/2025, and per-lot share counts are provided. These awards are tied to the company's 2019 Equity Incentive Plan.

Whether shares are freely tradable depends on vesting and Rule 144 conditions; look for future Form 4/Form 144 amendments reporting completed sales.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 04:42 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	E Trade Securities LLC 3 Edison Drive Alpharetta GA 30005	33528	154564.08	162678647	02/23/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	03/02/2022	Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			16969	03/02/2022	N/A
Class A Common Stock	03/08/2023	Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			16375	03/08/2023	N/A
Class A Common Stock	02/12/2024	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			13606	02/12/2024	N/A
Class A Common Stock	02/10/2025	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			30556	02/10/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ironwood Pharmaceuticals' Form 144 (IRWD) indicate about proposed share sales?

It indicates proposed resale of Class A common stock originating from restricted stock unit awards. The filing lists grant dates and per-lot share counts, such as 16,969 and 16,375, but does not show aggregate proceeds or sale timing.

Which RSU grant dates are listed on the IRWD Form 144 excerpt?

The excerpt lists RSU grant dates of 03/02/2022, 03/08/2023, 02/12/2024, and 02/10/2025. Each line pairs a grant date with a specific share count tied to the company's equity incentive plan.

How many shares are shown in the Form 144 entries for IRWD?

Per-lot counts are shown for four RSU awards: 16,969, 16,375, 13,606, and 30,556. The filing provides these lot sizes but does not aggregate them into a total for resale in the excerpt.

Does the Form 144 excerpt show completed sales or proceeds for IRWD?

No; the excerpt lists securities to be sold from RSU awards and notes previous three-month sales section, but it does not report aggregate proceeds or completed sale transactions in the provided text.